On the basis of the evidence above and findings from our study, we postulated that ICIs plus targeted therapies might reduce HCC recurrence by inhibiting PD-L1/PD1 and VEGF, which mediate the immune system to treat microscopic pre-existing tumors or intrahepatic metastases, and inhibit tumor immune escape. The gene discussed is VEGFA; the disease is neoplasm.